Cas 121123-17-9 Cefprozil Monohydrate Broad Spectrum Semi Synthetic Antibiotic API

Cefprozil hydrate Cas No 121123-17-9 API; Anti-biotic; Broad-spectrum semi-synthetic antibiotics

Specification:

Product Description:

Cefprozil is the second generation of cephalosporins and has a broad spectrum of antimicrobial action.

It is the first oral cephalosporin antibiotic approved by FDA for the treatment of otitis media and sinusitis in children. It is superior to cefclone in antimicrobial activity and is suitable for infants and adults over 6 months of age.

The bactericidal mechanism of the drug is that it binds to penicillin-binding proteins (PBPs) on the bacterial cell membrane and blocks the synthesis of the bacterial cell wall, leading to the dissolution and death of the bacteria.

Product Use:

To suppurative pneumonia and streptococcus agalactiae, to methicillin sensitive gold staphylococcus action is strong, to haemophilus influenzae and other inhibition. For mild to moderate skin infections and respiratory infections caused by sensitive bacteria. The second generation of cephalosporin antibiotics, with a broad spectrum of antibacterial action

Product Catalogue:

About us

Zhejiang chemical import and export co., LTD. (zhejiang), formerly known as zhejiang branch of China national chemical import and export corporation, was established in December 1980. In 1988, he was transferred from Sinochem Corporation to be in charge of Zhejiang Provincial Department of Commerce and was renamed Zhejiang Chemical Import and Export Company. In 2003, the company changed its name to Zhejiang Chemical Import and Export Co., Ltd after the reform of state-owned enterprise shareholding system.

In 2008, it was incorporated into Zhejiang International Trade Group (one of the top 500 enterprises in China) and became the core member of the group's business circulation sector. The registered capital of the company is 72.5 million yuan, of which 38% are owned by the state and 62% are owned by employees.
There are 195 employees in the company, more than 79% of whom have bachelor's degree, 36% of whom are graduate students, and more than 90% of the salesmen have pharmaceutical and chemical background. The company is mainly engaged in the import and export trade of pharmaceutical raw materials and intermediates, dyes, pesticides, basic chemicals, fine chemicals, food and feed additives, pharmaceutical preparations and other products. The company has established close economic and trade relations with more than 100 countries and regions around the world. The company has wholly-owned subsidiaries Ruike International Trade Co., Ltd., Zhejiang Ruikai Chemical Co., Ltd., Zhejiang Fukai Import and Export Co., Ltd., joint-stock enterprise Zhejiang Aotokang Pharmaceutical Group Co., Ltd.
In recent years, especially since the establishment of the new team in 2019, the company has adhered to the development led by the party building, energized by reform, and improved efficiency by management. The company has shown a steady upward momentum of development. In 2020, the company achieved revenue of 3.337 billion yuan, total profit of 56.12 million yuan, total import and export of 450 million dollars.

In 2019, the company was rated as China Council for the Promotion of International Trade (CCPIT) Recommended Certification Enterprise, Top 100 International Pharmaceutical Enterprises -- a high-quality supplier and partner in the international market; In 2020, Zhejiang Provincial Department of Commerce and other units rated as the province's epidemic prevention and medical materials import outstanding contribution enterprise, Zhejiang Provincial Tax Bureau identified as the export tax rebate enterprises.